169 related articles for article (PubMed ID: 37693293)
1. Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.
Jovanoski N; Bowes K; Brown A; Belleli R; Di Maio D; Chadda S; Abogunrin S
Lung Cancer Manag; 2023 Sep; 12(3):LMT60. PubMed ID: 37693293
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Aspects of survival from colorectal cancer in Denmark.
Iversen LH
Dan Med J; 2012 Apr; 59(4):B4428. PubMed ID: 22459726
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence.
Bowes K; Jovanoski N; Brown AE; Di Maio D; Belleli R; Chadda S; Abogunrin S
Med Oncol; 2022 Oct; 40(1):4. PubMed ID: 36308605
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
[TBL] [Abstract][Full Text] [Related]
7. Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States.
Sharma R; Ogale S; Smith NJ; Lee JS
Cancer Med; 2023 Mar; 12(6):7450-7458. PubMed ID: 36420712
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
Guo K; Lu J; Lou Y; Zheng S
Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
[TBL] [Abstract][Full Text] [Related]
9. Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021.
Yan JT; Jin Y; Lo E; Chen Y; Hanlon Newell AE; Kong Y; Inge LJ
Oncol Ther; 2023 Sep; 11(3):343-360. PubMed ID: 37330972
[TBL] [Abstract][Full Text] [Related]
10. Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival.
Shin DW; Cho JH; Yoo JE; Cho J; Yoon DW; Lee G; Shin S; Kim HK; Choi YS; Kim J; Zo JI; Shim YM
Cancer Res Treat; 2021 Oct; 53(4):1057-1071. PubMed ID: 33705624
[TBL] [Abstract][Full Text] [Related]
11. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy.
Cortinovis DL; Perrone V; Giacomini E; Sangiorgi D; Andretta M; Bartolini F; Taurino G; Belfiore M; Sicari E; Degli Esposti L
Pharmaceuticals (Basel); 2023 Feb; 16(3):. PubMed ID: 36986463
[TBL] [Abstract][Full Text] [Related]
13. Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review.
Ortega-Franco A; Calvo V; Franco F; Provencio M; Califano R
Transl Lung Cancer Res; 2020 Dec; 9(6):2656-2673. PubMed ID: 33489825
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study.
Cai B; Fulcher N; Boyd M; Spira A
Thorac Cancer; 2021 Jul; 12(14):2055-2064. PubMed ID: 34028984
[TBL] [Abstract][Full Text] [Related]
17. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
18. Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC.
Moore S; Leung B; Wu J; Ho C
JTO Clin Res Rep; 2020 Nov; 1(4):100083. PubMed ID: 34589962
[TBL] [Abstract][Full Text] [Related]
19. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
